- In April 2025, Daiichi Sankyo reported that a planned interim analysis of the Phase 3 DESTINY‑Breast09 trial demonstrated that combining ENHERTU (trastuzumab deruxtecan) with pertuzumab produced a highly significant and clinically meaningful improvement in progression‑free survival versus the standard taxane, trastuzumab, and pertuzumab (THP) regimen as first‑line therapy for patients with HER2‑positive metastatic breast cancer
- In June 2024, Zydus Lifesciences Limited and global pharmaceutical company Dr. Reddy’s Laboratories entered into a licensing agreement to co‑market a pertuzumab biosimilar in India. Developed in‑house by the Zydus Research Centre, this biosimilar provides a vital treatment option for patients with HER2‑positive breast cancer
- In November 2023, Chugai Pharmaceutical Co., Ltd. introduced Phesgo—a subcutaneous combination of pertuzumab, trastuzumab, and vorhyaluronidase alfa—in MA and IN. It is approved for treating HER2‑positive breast cancer, as well as advanced or recurrent HER2‑positive colorectal cancer that has progressed following chemotherapy and is not amenable to curative resection
